Olalekan Badiru
Neurology · Brooklyn, NYNPI 1114172467
Payments from drug & device makers
Across 290 payments — averaging $271.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$73K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$939
- Lundbeck LLC$825
- Johnson & Johnson$708
- plus $1K from 8 others
What the payments were for
- Food & beverage$6,627100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $72,605 |
| Alkermes, Inc. | 52 | $1,229 |
| Neurocrine Biosciences, Inc. | 55 | $1,089 |
| Otsuka America Pharmaceutical, Inc. | 39 | $939 |
| Lundbeck LLC | 30 | $825 |
| Johnson & Johnson | 32 | $708 |
| E.r. Squibb & Sons, L.L.C. | 18 | $548 |
| Teva Pharmaceuticals USA, Inc. | 13 | $265 |
| Bioxcel Therapeutics, Inc. | 8 | $222 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $200 |
| Sunovion Pharmaceuticals Inc. | 2 | $47 |
| Janssen Scientific Affairs, LLC | 1 | $36 |
| Brainsway USA Inc | 1 | $33 |
| Corium, LLC | 1 | $25 |
How this compares
$78,771 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 33 | $281,695 |
| Invega SustennaPaliperidone Palmitate | 25 | $48,093 |
| Wellbutrin XlBupropion Hcl | 11 | $20,972 |
| Lurasidone Hcl | 11 | $3,093 |
| Clozapine | 24 | $1,018 |
| Fluphenazine Decanoate | 12 | $938 |
| Haloperidol | 44 | $922 |
| Risperidone | 87 | $568 |
| Hydroxyzine Hcl | 52 | $558 |
| Doxepin Hcl | 38 | $451 |
| Quetiapine Fumarate | 62 | $403 |
| Trazodone Hcl | 96 | $320 |
| Mirtazapine | 26 | $230 |
| Olanzapine | 19 | $226 |
| Duloxetine Hcl | 33 | $223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,089 | $281,69533 claims |
| Johnson & JohnsonInvega Sustenna | $708 | $48,09325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.
Other neurology in Brooklyn
- Idan SharonBrooklyn$2.1M
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
- Bennett MyersAmherst$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.